Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit
Introduction and Objectives: Ubiquitin-specific proteases (USPs) act as proto-oncogenes or tumor suppressors in a wide variety of cancers. In this study, we intended to explore the role of USP1 in hepatocellular carcinoma (HCC). Materials and Methods: The clinical significance of USP1 in HCC was ana...
Main Authors: | Zhangbin Chen, Yifei Ma, Zhitang Guo, Dingyuan Song, Zili Chen, Min Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268122000114 |
Similar Items
-
Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression
by: Peng Sun, et al.
Published: (2024-07-01) -
Gene Signature and Prognostic Value of Ubiquitin-Specific Proteases Members in Hepatocellular Carcinoma and Explored the Immunological Role of USP36
by: Weijie Sun, et al.
Published: (2022-06-01) -
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
by: Jie Zhu, et al.
Published: (2021-11-01) -
Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
by: Guangxin Li, et al.
Published: (2022-11-01) -
The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
by: Wei Sun, et al.
Published: (2024-04-01)